SCHEMBL5836722

SCHEMBL5836722

O=C(OCc1ccccc1)c1ccccc1Oc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.57
ALDH1A1 P00352 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
TSHR P16473 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MAPK1 P28482 2/20 0.56
CYP3A4 P08684 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NR4A1 P22736 1/20 0.53
NR4A2 P43354 1/20 0.53
NR4A3 Q92570 1/20 0.53
POLB P06746 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAOB P27338 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
PARP10 Q53GL7 1/20 0.50
CTNNB1 P35222 1/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27462412 0.91 SMN1; SMN2 (0.66) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL6167480 0.89 NR4A2 (0.59) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL10930452 0.87 ALDH1A1 (0.58) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL709808 0.86 ALDH1A1 (0.54) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL2112521 0.85 HTT (0.63) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL4415350 0.85 HTT (0.75) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL9574717 0.83 HTT (0.73) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL31336015 0.82 MAOB (0.58) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL4943007 0.82 MAOB (0.58) HTTALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL5836718 0.81 SLC6A2 (0.67) ALDH1A1TDP1SMN1; SMN2NR4A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119201-B2 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC (US) 2006-10-10 US disclosed
EP-1501515-B1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-11-02 EP disclosed
EP-1501515-A1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-02 EP disclosed
US-20040006057-A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER PRODUCTS INC. 2004-01-08 US disclosed
WO-2003090752-A1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006057-A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 HTT 4698/4885ALDH1A1 300/4885TDP1 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.